214 related articles for article (PubMed ID: 17620904)
1. Immunostimulatory sequences in immunotherapy.
Blanks DA
Curr Opin Otolaryngol Head Neck Surg; 2007 Aug; 15(4):281-5. PubMed ID: 17620904
[TBL] [Abstract][Full Text] [Related]
2. DNA-based immunotherapy to treat atopic disease.
Tsalik EL
Ann Allergy Asthma Immunol; 2005 Nov; 95(5):403-10; quiz 410-1, 451. PubMed ID: 16312161
[TBL] [Abstract][Full Text] [Related]
3. Use of CpG oligonucleotides in treatment of asthma and allergic disease.
Fonseca DE; Kline JN
Adv Drug Deliv Rev; 2009 Mar; 61(3):256-62. PubMed ID: 19167442
[TBL] [Abstract][Full Text] [Related]
4. Immune modulatory oligonucleotides in the prevention and treatment of allergen-induced eustachian tube dysfunction in the animal model.
Blanks DA; Ebert CS
Curr Allergy Asthma Rep; 2008 Nov; 8(6):508-12. PubMed ID: 18940142
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
Jahrsdörfer B; Weiner GJ
Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
[TBL] [Abstract][Full Text] [Related]
6. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
Wang J; Zhang W; He A; Zhao W; Cao X
Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566
[TBL] [Abstract][Full Text] [Related]
7. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
[TBL] [Abstract][Full Text] [Related]
8. DNA-based approaches to the treatment of allergies.
Spiegelberg HL; Raz E
Curr Opin Mol Ther; 2002 Feb; 4(1):64-71. PubMed ID: 11883696
[TBL] [Abstract][Full Text] [Related]
9. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
[TBL] [Abstract][Full Text] [Related]
10. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.
Wilson KD; de Jong SD; Tam YK
Adv Drug Deliv Rev; 2009 Mar; 61(3):233-42. PubMed ID: 19232375
[TBL] [Abstract][Full Text] [Related]
11. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.
Harandi AM; Holmgren J
Curr Opin Investig Drugs; 2004 Feb; 5(2):141-5. PubMed ID: 15043387
[TBL] [Abstract][Full Text] [Related]
12. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
[TBL] [Abstract][Full Text] [Related]
13. Oral and intraperitoneal administration of phosphorothioate oligodeoxynucleotides leads to control of Cryptosporidium parvum infection in neonatal mice.
Barrier M; Lacroix-Lamandé S; Mancassola R; Auray G; Bernardet N; Chaussé AM; Uematsu S; Akira S; Laurent F
J Infect Dis; 2006 May; 193(10):1400-7. PubMed ID: 16619188
[TBL] [Abstract][Full Text] [Related]
14. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
Chaung HC
Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
[TBL] [Abstract][Full Text] [Related]
16. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.
Miles SA; Sandler AD
Adv Drug Deliv Rev; 2009 Mar; 61(3):275-82. PubMed ID: 19186194
[TBL] [Abstract][Full Text] [Related]
17. CpG-ODN increases resistance of olive flounder (Paralichthys olivaceus) against Philasterides dicentrarchi (Ciliophora: Scuticociliatia) infection.
Lee EH; Kim KH
Fish Shellfish Immunol; 2009 Jan; 26(1):29-32. PubMed ID: 18992348
[TBL] [Abstract][Full Text] [Related]
18. CpG motifs as possible adjuvants for the treatment of allergic diseases.
Bohle B
Int Arch Allergy Immunol; 2002 Nov; 129(3):198-203. PubMed ID: 12444316
[TBL] [Abstract][Full Text] [Related]
19. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
Klinman DM; Klaschik S; Sato T; Tross D
Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
[TBL] [Abstract][Full Text] [Related]
20. CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung.
Ashino S; Wakita D; Zhang Y; Chamoto K; Kitamura H; Nishimura T
Int Immunol; 2008 Feb; 20(2):259-66. PubMed ID: 18156622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
